Latest Headlines

  1. Kindeva Announces Leadership Transition To Drive Strategic Growth 1/16/2026

    Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, today announced a series of planned leadership transitions designed to position the company for accelerating growth in its core businesses focused on parenteral and inhaled drug delivery. 

  2. Cellares Expands Global Footprint With New European IDMO Smart Factory In Leiden 1/16/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity.

  3. Rakuten Medical And LOTTE Biologics Sign Manufacturing Agreement To Support Biopharmaceuticals In Global Oncology Program 1/14/2026

    Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical’s production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy.

  4. CDMO GBI Biomanufacturing Announces New President 1/6/2026

    GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.

  5. Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK 12/22/2025

    This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

  6. Sanofi Toronto Equipment Assets Auction Announced For January 2026 12/19/2025

    Federal Equipment Company, a trusted global provider of surplus pharmaceutical and chemical processing equipment, announced it will conduct a two-day online auction on behalf of Sanofi featuring quality process and laboratory equipment surplus to the company’s ongoing operational needs.

  7. Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics 12/18/2025

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.

  8. Minaris And Cell And Gene Therapy Catapult Announce Collaboration To Advance Delivery Methods For Cell And Gene Therapies 12/18/2025

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization specializing in the advancement of the CGT industry, today announced a collaboration to develop CGT delivery technologies to enable more robust manufacturing processes, improved quality, and lower cost of goods.

  9. Asimov Launches CHO Edge Rapid Pools To Bridge Biologics Discovery And CMC With Predictive Stable Expression 12/16/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of CHO Edge Rapid Pools, a high-throughput stable CHO expression system that brings CMC-grade performance and assurance to biologics discovery teams.

  10. Bora Pharmaceuticals And Corealis Pharma Forge Strategic Alliance To Deliver Seamless, End-To-End Oral Solid Dose Development 12/9/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.